Navigation Links
Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter

STEWARTVILLE, Minn., Feb. 4 /PRNewswire-FirstCall/ -- Rochester Medical Corporation (Nasdaq: ROCM) today announced operating results for its first quarter ending December 31, 2007.

The Company reported sales of $8,223,000 for the current quarter compared to $7,512,000 for the first quarter of last year. It also reported net income of $272,000 or $.02 per diluted share compared to a net income of $31,467,000 or $2.59 per diluted share for the first quarter of last year. Net income for the first quarter of last year included $31,305,000 received from lawsuit settlements net of taxes.

The approximately 9% overall increase in sales resulted from a 31% increase in Rochester Medical Branded Sales partially offset by a 21% decrease in Private Label Sales. The Company expects that the decrease in Private Label Sales for the quarter is temporary and is attributable to the timing of large Private Label orders. The Company believes that Private Label Sales will improve throughout the year.

Net income adjusted for certain non-recurring unusual items and certain recurring non-cash expenses, or "Non-GAAP Net Income" for the current quarter is $686,000 or $.05 per diluted share compared to Non-GAAP Net Income of $1,388,000 or $.11 per diluted share for the first quarter of last year. The decrease for this quarter is primarily attributable to increased investment in Sales and Marketing Programs.

Commenting on today's announcement Rochester Medical CEO and President Anthony J. Conway said, "I am very pleased with our progress this quarter. The 31% organic growth rate in our Rochester Medical Branded Sales demonstrates solid initial success resulting from our strategic decision to increase investments in Sales and Marketing. I firmly believe these investments will continue to drive strong Branded Sales growth.

"The decrease in Private Label Sales for the quarter is a timing issue, and we expect Private Label Sales to normalize throughout the year. Led by continued solid growth of Rochester Medical Branded Sales, we expect greater overall sales in Q2."

Conway went on to say, "We will continue our commitment to expanded Sales and Marketing programs, and I believe it will lead to significantly increased revenue and income in the future."

Rochester Medical has provided Non-GAAP Net Income in addition to earnings calculated in accordance with generally accepted accounting principles (GAAP) because management believes Non-GAAP Net Income provides a more consistent basis for comparisons that are not influenced by certain charges and non-cash expenses and are therefore helpful in understanding Rochester Medical's underlying operating results. Non-GAAP Net Income is not a measure of financial performance under GAAP, and should not be considered an alternative to net income or any other measure of performance or liquidity under GAAP. Non-GAAP Net Income is not comparable to information provided by other companies. Non-GAAP Net Income has limitations as an analytical tool and should not be considered in isolation or as a substitution for analysis of our results as reported under GAAP.

Reconciliations of Net Income and Non-GAAP Net Income are presented at the end of this press release.

The Company will hold a quarterly conference call this afternoon to discuss its earnings report. The call will begin at 4:00 p.m. Central Standard Time (5:00 p.m. eastern time). This call is being webcast by Thomson/CCBN and can be accessed at Rochester Medical's website at To listen live to the conference call via telephone, call:

Domestic: 1-888-680-0894, password 57867978

International: 617-213-4860, password 57867978

Pre Registration:

Replay will be available for seven days at or via

telephone at:

Domestic: 1-888-286-8010, password 37130118

International: 617-801-6888, password 37130118

The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (

This press release contains forward-looking statements that involve risks and uncertainties, including the uncertainty of estimated revenues and profits, as well as the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of private label sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2007.

Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications. The Company markets under its own Rochester Medical(R) brand and under existing private label arrangements.

For further information, please contact Anthony J. Conway, President and Chief Executive Officer of Rochester Medical Corporation at (507) 533-9600. More information about Rochester Medical is available on its website at


Reconciliation of Reported GAAP Net Income to Non-GAAP Net Income

For the three months ended

December 31, 2007

Three months ended

December 31,

2007 2006

GAAP Net Income as Reported $272,000 $31,467,000

Diluted EPS as Reported $0.02 $2.59

Adjustments for non-recurring unusual


Settlement income after taxes (1) - (31,305,000)

Deferred revenue (2) - (39,000)

Subtotal - (31,344,000)

Adjustments for recurring non-cash


Intangible Amortization (3) 163,000 163,000

FAS 123R Compensation Expense (4) 251,000 1,102,000

Subtotal 414,000 1,265,000

Non-GAAP Net Income $686,000 $1,388,000

Non-GAAP Diluted EPS $0.05 $0.11

Weighted Average Shares - Diluted 12,587,229 12,158,281

(1) Settlement income received November 20, 2006 from Premier, Inc of

$5,155,000 and December 14, 2006 from CR Bard, Inc. of $33,450,000

after taxes. This adjustment reduces net income for amounts received

net of taxes paid in connection with one-time settlement of certain

litigation. These amounts were recorded in Other Income in the

Statement of Operations for the fiscal year ended September 30, 2007.

(2) Deferred revenue from a $1,000,000 fee paid by Coloplast A/S in June

2002 for marketing rights to our antibacterial Release NF foley

catheter. These rights with Coloplast A/S were cancelled by mutual

agreement in March 2007, thus accelerating the recognition of the

remaining amount as all conditions for revenue recognition have now

been met. Also includes a $200,000 fee paid by Hollister for

marketing rights to our hydorphilic intermittent catheter in September

2003. The fee paid by Hollister was fully recognized in December

2006. This adjustment reduces net income related to the realization

of certain one-time revenue from marketing rights. The amounts were

recorded in net sales in the Statement of Operations.

(3) Amortization of the intangibles acquired in June 2006 asset

acquisition from Coloplast AS and Mentor Corporation. Management

believes these assets are appreciating. This adjustment adds back

amortization expense for the three months ended December 31, 2007 and

2006 related to certain intangibles.

(4) Compensation expense mandated by SFAS 123R. This adjustment adds back

the compensation expense recorded when stock options are granted to

employees and directors for the three months ended December 31, 2007

and 2006.

Condensed Balance Sheets


December 31, September 30,

2007 2007


Current Assets

Cash and equivalents $8,736,066 $6,671,356

Marketable securities 28,676,923 30,465,244

Accounts receivable 4,913,202 5,527,518

Inventories 8,588,850 7,698,889

Prepaid expenses and other

assets 508,563 6,480

Deferred income tax asset 828,588 876,032

Total current assets 52,252,192 51,245,519

Property and equipment, net 9,683,109 9,679,035

Deferred income tax asset 621,664 571,721

Patents, net 256,316 257,353

Intangible assets, net 7,590,075 7,821,562

Goodwill 5,761,715 5,920,255

Total Assets $76,165,071 $75,495,445

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $2,233,178 $1,091,874

Accrued expenses 920,163 1,978,937

Short-term debt 1,809,106 1,849,463

Total current liabilities 4,962,447 4,920,274

Long-term liabilities

Long-term debt 5,774,352 6,066,246

Total long term liabilities 5,774,352 6,066,246

Stockholders' equity 65,428,272 64,508,925

Total Liabilities and Stockholder

Equity $76,165,071 $75,495,445

Summary Statements Of Operations


Three months ended

December 31,

2007 2006

Sales $8,223,288 $7,511,966

Cost of sales 4,082,485 3,736,344

Gross profit 4,140,803 3,775,622

Gross profit % 50% 50%

Costs and expense:

Marketing and selling 2,224,365 1,233,662

Research and development 228,943 202,770

General and administrative 1,615,118 2,049,146

Total operating expenses 4,068,426 3,485,578

Income from operations 72,377 290,044

Other income (expense)

Interest income 453,340 74,850

Interest expense (149,489) (159,647)

Other income - 38,605,000

Net income before income taxes 376,228 38,810,247

Income tax expense 104,674 7,343,640

Net income $271,554 $31,466,607

Earnings per common share - Basic $0.02 $2.83

Earnings per common share - Diluted $0.02 $2.59

Weighted Average Shares:

Basic 11,730,234 11,102,034

Weighted Average Shares:

Diluted 12,587,229 12,158,281

SOURCE Rochester Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading ... a nationwide oncology Clinical Nurse Educator (CNE) network, which will ... need for communication among health care professionals to enhance the ... nurses, office staff, and other health care professionals to help ... breast cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):